Guangxi Medical University is the lead sponsor of 9 current clinical trials in our China register. 4 are recruiting patients now. The most common phase is Observational. The most-studied condition is Hepatocellular Carcinoma.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma
NCT06405321 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma
|
Observational | Recruiting | 2019-01 | China |
|
Comparison of Partial Stomach-Partitioning and Conventional Gastrojejunostomy for the Treatment of Gastric Outlet Obstruction in Advanced Gastric Cancer
NCT07561073 · ClinicalTrials.gov ↗ · Gastric Cancer
|
Not applicable | Recruiting | 2026-10 | China |
|
Multimodal Imaging and Digital Pathology for Prostate Cancer Prediction
NCT07614256 · ClinicalTrials.gov ↗ · Prostate Cancer (Diagnosis), Clinically Significant Prostate Cancer
|
Observational | Recruiting | 2025-05 | China |
|
Adjuvant TACE in HCC With High-risk Recurrence Factors
NCT07417397 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Adjuvant, Transarterial Chemoembolization
|
Phase 3 | Recruiting | 2026-02 | China |
|
The Workplace-Based Hypertension Management Program
NCT07265193 · ClinicalTrials.gov ↗ · Hypertension
|
Not applicable | Not yet open | 2026-01 | China |
|
AI Multimodal Model for Predicting CRPC Progression Risk
NCT07658573 · ClinicalTrials.gov ↗ · Prostate Cancer, Castration-Resistant Prostate Cancer
|
Observational | Active, closed | 2025-06 | China |
|
AI Multimodal Model for Liver Cancer Diagnosis and Prognosis
NCT07658586 · ClinicalTrials.gov ↗ · Liver Cancer, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma (Icc)
|
Observational | Active, closed | 2025-12 | China |
|
Intelligent Screening and Precision Diagnosis of Prostate Cancer Based on Multimodal Data
NCT07631806 · ClinicalTrials.gov ↗ · Prostate Cancer With PSA Gray Zone
|
Observational | Active, closed | 2026-05 | China |
|
PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma
NCT05340270 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Neoadjuvant Therapy, PD-1 Inhibitor
|
Phase 2 | Active, closed | 2022-07 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 9 | 4 |
A trial with sites in more than one country appears in each of those registers.
Sponsors with the most current trials registered for this condition.
Guangxi Medical University is the lead sponsor of 9 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 4 of its 9 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.